Does the small tyrosine kinase inhibitor imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?

Review Series - Inflammation & Fibrosis * Fibrocytes and fibrosis

(2012) R. Bucala   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis

(2011) Anagha A. Divekar et al.   CLINICAL IMMUNOLOGY

cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets

(2011) S. L. Subramanian et al.   DIABETOLOGIA

Involvement of ATP-sensitive Potassium (KATP) Channels in the Loss of Beta-cell Function Induced by Human Islet Amyloid Polypeptide

(2011) Maud Soty et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients

(2011) Roberto Ciarcia et al.   JOURNAL OF CELLULAR PHYSIOLOGY

IL-1 Blockade Attenuates Islet Amyloid Polypeptide-Induced Proinflammatory Cytokine Release and Pancreatic Islet Graft Dysfunction

(2011) C. Westwell-Roper et al.   JOURNAL OF IMMUNOLOGY

Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?

(2010) S. Zraika et al.   DIABETOLOGIA

Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?

(2010) Stephen Fitter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Protein Tyrosine Kinase Inhibitor, Imatinib Mesylate (Gleevec), Improves Erectile and Vascular Function Secondary to a Reduction of Hyperglycemia in Diabetic Rats

(2010) Serap Gur et al.   Journal of Sexual Medicine

Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease

(2010) Gen He et al.   NATURE

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes

(2009) Dariush Mokhtari et al.   CLINICAL SCIENCE

Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice

(2009) M. S. Han et al.   DIABETES

Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo

(2009) Mandy L. Ballinger et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia

(2009) Stefania Mariani et al.   LEUKEMIA RESEARCH

c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice

(2009) Gonzalo I. Cancino et al.   NEUROBIOLOGY OF AGING

Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes

(2009) Peter J. Little et al.   TheScientificWorldJOURNAL

IRS1-Independent Defects Define Major Nodes of Insulin Resistance

(2008) Kyle L. Hoehn et al.   Cell Metabolism

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Ultrastructure of Islet Microcirculation, Pericytes and the Islet Exocrine Interface in the HIP Rat Model of Diabetes

(2008) Melvin R. Hayden et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Role of platelet-derived growth factors in physiology and medicine

(2008) J. Andrae et al.   GENES & DEVELOPMENT

High glucose-induced upregulation of Rho / Rho-kinase via platelet-derived growth factor receptor−β increases migration of aortic smooth muscle cells

(2008) Noboru Akiyama et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

(2008) M. Breccia et al.   LEUKEMIA RESEARCH

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet

(2007) Robert Hägerkvist et al.   CLINICAL SCIENCE

Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)

(2007) Apostolos Tsapas et al.   LEUKEMIA RESEARCH